Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Share-based Compensation: 2013-2025

Historic Share-based Compensation for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $6.3 million.

  • Amphastar Pharmaceuticals' Share-based Compensation rose 12.53% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.7 million, marking a year-over-year increase of 14.32%. This contributed to the annual value of $24.4 million for FY2024, which is 20.38% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Share-based Compensation stood at $6.3 million for Q3 2025, which was down 1.33% from $6.4 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Share-based Compensation peaked at $8.4 million during Q1 2025, and registered a low of $3.9 million during Q4 2021.
  • For the 3-year period, Amphastar Pharmaceuticals' Share-based Compensation averaged around $6.0 million, with its median value being $5.8 million (2024).
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Share-based Compensation slumped by 30.39% in 2022, and later rose by 21.85% in 2024.
  • Amphastar Pharmaceuticals' Share-based Compensation (Quarterly) stood at $3.9 million in 2021, then rose by 11.79% to $4.3 million in 2022, then increased by 7.39% to $4.6 million in 2023, then increased by 21.85% to $5.6 million in 2024, then increased by 12.53% to $6.3 million in 2025.
  • Its Share-based Compensation stands at $6.3 million for Q3 2025, versus $6.4 million for Q2 2025 and $8.4 million for Q1 2025.